Andy Hahn, MD, a resident at the University of Utah School of Medicine, discusses therapy for patients with prostate cancer whom neither docetaxel or abiraterone acetate (Zytiga) is an option.
Andy Hahn, MD
Advertisement
Articles by Andy Hahn, MD
Andy Hahn, MD, resident, University of Utah School of Medicine, discusses abiraterone acetate (Zytiga) versus docetaxel in the treatment of patients with prostate cancer.
Andy Hahn, MD, resident, University of Utah School of Medicine, discusses patient selection for abiraterone acetate (Zytiga) versus docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC).
Advertisement
Latest Updated Articles
Dr. Hahn on Patient Selection for Abiraterone Versus Docetaxel in mHSPCPublished: May 31st 2018 | Updated:
Dr. Hahn Discusses Abiraterone Versus Docetaxel in Prostate CancerPublished: June 27th 2018 | Updated:
Dr. Hahn on Patients With Prostate Cancer Whom Neither Docetaxel or Abiraterone is an OptionPublished: September 11th 2018 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
5